At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Afib 2gether TM Mobile Applicationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Shared Decision-Making: Implementing the AFib 2getherTM Mobile App
In Brief
A clinical study evaluating Afib 2gether TM Mobile Application for Atrial Fibrillation New Onset. Completed, enrolled 50 participants across 1 site.
Detailed Summary
Shared Decision-Making: AFib 2gether™ is a research study that focuses on a mobile application developed by Pfizer, Inc with consultation from Dr McManus' called AFib 2gether™. Through this app, patients can determine their risk of stroke due to atrial fibrillation and prioritize questions and concerns for discussion with their cardiology provider.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation New Onset
CountriesUnited States
CollaboratorsPfizer
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartNov 2019
Primary CompletionJun 2020
TodayJul 2026
First PostedOct 8, 2019
Enrollment StartNov 1, 2019
Primary CompletionJun 26, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.7 years ago
Interventions
Afib 2gether TM Mobile Applicationdevice
The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.